Edgewise Therapeutics, Inc.

BOULDER, Colo., Nov. 9, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 3rd Annual Healthcare Innovation Conference Fireside chat: Tuesday, November 10, 2026 at 8:00 am ET 2026 Truist Biopharma Symposium Fireside chat: Thursday, November 12, 2026 at 10:30 am ET The webcasts can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference.

– Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO ₂ as the primary endpoint – – STRATUS-HCM on track to start in the fourth quarter of 2026 – BOULDER, Colo., Nov. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced favorable feedback from its End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for EDG-7500 in symptomatic obstructive and nonobstructive hypertrophic cardiomyopathy (HCM).

–  Published the differentiated mechanism of action of EDG-7500 that targets the regulatory light chain – –  Phase 3 trial for EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) on track to initiate by year-end 2026 – –  Dosed first patient in Phase 2 EQUINOX-HFpEF trial of EDG-15400 in heart failure with preserved ejection fraction (HFpEF) – BOULDER, Colo., Nov. 4, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today reported financial results for the third quarter of 2026 and recent business highlights.

BOULDER, Colo., Nov. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage cardiovascular biopharmaceutical company, today announced that on October 30, 2026, Edgewise granted inducement stock options to purchase a total of 17,250 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 8,626 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").